The federal government launched a behavioral health research initiative, with $50 million allocated to match state investments in psychedelic research, including psilocybin, a hallucinogenic compound ...

Despite this, the Food and Drug Administration didn’t formally review a psychedelic compound for federal regulation until ...

U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic ...

Here are four ways UC San Francisco researchers are pioneering new treatment frontiers in depression, Parkinson’s, and ...

In April, Vail Health’s Behavioral Health Innovation Center will kick off the second of two studies aimed at targeting depression. The OPTIMIZE study will examine the impacts of psilocybin, the active ...

Both ABA and RW groups demonstrate elevated preference for novel social over other novel stimuli. Empty symbols represent SAL-treated mice; filled symbols represent psilocybin-treated mice. Data are ...

A new study published in Progress in Neuropsychopharmacology & Biological Psychiatry has found that a single moderate dose of psilocybin produces rapid and lasting antidepressant-like effects in rats, ...

Kennedy, Jr. Meanwhile, plenty of people aren’t waiting for government approval before experimenting: About 8 million US ...

Kosuke Kato, lead author, former professor at Emory University, where the study was initiated and funded, and current professor at Baylor College of Medicine. As revenues from the anti-aging market-- ...